Cowen's Tepezza Survey Confirms Investor Expectations Remain Low, Horizon Therapeutics (HZNP) PT Reiterated at $115
Tweet Send to a Friend
Cowen analyst Ken Cacciatore reiterated an Outperform rating and $115.00 price target on Horizon Therapeutics (NASDAQ: HZNP) investors remain too ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
